Seed investment funded the development of Hey Seven’s AI-native platform, now helping gaming operators identify, engage, and develop premium and emerging premium players.

LAS VEGAS, July 21, 2026 — Hey Seven today announced that Bettor Capital, a leading venture capital firm focused on the real-money online gaming sector, was the company’s seed investor and first institutional investor. Bettor Capital’s seed investment funded the development of Hey Seven’s AI-native player development platform, which is now being deployed with gaming operators across land-based, online, and omnichannel environments.

Gaming operators face growing pressure to increase revenue and build more personalized, high-value player relationships with limited staff. Human player development teams can only maintain a limited number of high-touch relationships, while emerging premium players often stay hidden inside legacy segmentation models. Hey Seven enables operators to identify high-potential players earlier, communicate with greater relevance, and deliver host-level attention at scale.

“Bettor Capital understood what we were building before anyone else did,” said Tal Rubinstein, CEO and Co-Founder of Hey Seven. “As our first institutional investor, they gave us the conviction and the resources to build a platform that operators can put to work from day one.”

Because Bettor Capital funded the platform’s development, operators can invest in proven technology that delivers earlier identification of tomorrow’s VIPs, stronger player relationships, and measurable incremental revenue, not in financing product development.

“Player development represents a large opportunity for efficiency gains and optimization, where AI and new technology can make a significant impact,” said David VanEgmond, Managing Partner of Bettor Capital. “Hey Seven combines deep operator expertise with purpose-built AI to address a problem every casino and digital gambling platform faces: building stronger relationships with premium players at scale. We backed this team early because we believe they have the experience and vision to define the next generation of player development.”

Bettor Capital invested in Hey Seven based on the founding team’s unique combination of tier-one gaming operating experience, enterprise technology expertise, and a shared vision for the future of AI in player development.

Together, Bettor Capital and Hey Seven share the conviction that AI will fundamentally transform player development, enabling operators to build deeper relationships, improve productivity, drive measurable incremental revenue, and strengthen long-term player loyalty.

About Bettor Capital Bettor Capital is an early-stage investment firm focused on the real-money online gaming market, primarily on opportunities within the software supply chain powering the continued digitalization of the gaming industry. Learn more at www.bettorcapital.com.

About Hey Seven, Inc. Hey Seven is the gaming industry’s first AI-native premium player development platform. Built specifically for casinos and integrated resorts, the platform unifies three forms of intelligence never before brought together in a single player profile—gaming intelligence, behavioral intelligence, and conversational intelligence. By combining autonomous AI with operator-defined guardrails, Hey Seven helps land-based, online, and omnichannel operators identify, develop, and grow premium and emerging premium players while delivering measurable incremental revenue. Founded by experienced tier-one gaming and technology executives, the company is built on three non-negotiable values: excellence, transparency, and accountability. Learn more at www.heyseven.ai.

SOURCE Hey Seven Inc.

Investment to Accelerate AI-Powered Safety and Operations Risk Intelligence for Construction, Utilities, Energy, and Industrial Sectors

CHARLOTTE, N.C. and PLEASANTON, Calif., July 21, 2026 — FactorLab, a Work Risk AI company dedicated to transforming how high-risk work is planned and delivered in distributed operations, today announced a strategic growth investment from Falfurrias Growth Partners (Falfurrias), a Charlotte-based private equity firm focused on growth-oriented, middle-market businesses. The investment will support FactorLab’s next phase of growth and customer success by funding continued development of FactorLab’s proprietary AI and machine learning technology; growth of its commercial organization; and expansion into adjacent industries that share a need for stronger safety and operational risk intelligence.

Headquartered in Pleasanton, California, FactorLab has established itself as an early leader in applying artificial intelligence to the conversations and decisions that happen on the front line, serving enterprise customers across construction, utilities, energy, and industrial markets. The company’s platform, SmartTagIt, uses proprietary natural language processing and machine learning models to capture and analyze frontline conversations, insights and how work actually gets done, giving leaders early visibility into where work is likely to break down. It turns previously untapped field data into real-time, actionable insights that help organizations identify and mitigate risk at the source, and surfaces new risk signals and game tape to empower crews to deliver on-time, prevent rework, and go home safe.

Over the past five years the platform has analyzed more than 2 million daily planning conversations across thousands of worksites and now operates more than 40 proprietary AI models. This scale powers normative benchmarks that let organizations measure field engagement, planning quality, and leadership performance against industry peers. Its mobile-first, intuitive interface drives high adoption among workers, replacing static checklists with a social, engaging experience that field crews and leaders use as an integral part of their daily workflow.

“We have built something fundamentally new for the industry: a platform that learns from real frontline conversations, decisions, and work practices to help organizations operate more safely, consistently, and productively,” said Barry Nelson, Founder and CEO of FactorLab. “Our customers have shown what is possible when frontline learning becomes part of daily operations, and we are deeply grateful for the trust they have placed in SmartTagIt. As we looked to accelerate our investment in technology, product innovation, and our team, we set out to find a partner who understood both the importance of our mission and the scale of the opportunity ahead. We chose Falfurrias because they share our vision, bring highly relevant experience across industrial and business-to-business markets, and have a proven track record helping AI-enabled companies scale with discipline and purpose.”

“We are excited to partner with Barry and the entire FactorLab team. The company has assembled an expansive, proprietary dataset in field safety and operational performance, and its technology delivers measurable value by embedding directly into frontline teams daily planning and operations,” said Michael Clifton and John Comly, Partners at Falfurrias. “FactorLab sits squarely within our focus on growing AI-enabled software businesses, and we believe our operational resources and sector experience will help the team rapidly scale its commercial engine, deepen its product capabilities, and extend its leadership across new sectors.” Bringing that experience to bear, Piers Wells, an Industry First executive with Falfurrias, will serve as a Director of FactorLab and brings deep industrial technology, operational, and go-to-market experience scaling businesses in FactorLab’s sectors.

Equity for this investment comes from Falfurrias Growth Partners I, a growth buyout fund strategy launched by Falfurrias Management Partners in 2023 and builds on the firm’s experience in the industrial technology and software sectors. Financial terms of the transaction were not disclosed.

Ernst & Young Capital Advisors LLC served as exclusive financial advisor to FactorLab on the transaction, and Holland & Knight LLP served as legal advisor to Falfurrias.

About FactorLab
FactorLab is a Work Risk AI company dedicated to helping distributed organizations transform safety, operational performance, and frontline leadership across construction, utilities, energy, and industrial operations. Its SmartTagIt platform uses proprietary AI and natural language processing models to capture and analyze frontline conversations, insights, and how work actually gets done to give leaders early visibility into risk across every worksite. It surfaces risk signals and game tape that legacy compliance tools cannot reach to empower crews to deliver on-time, prevent rework, and go home safe. FactorLab partners with leading operators in complex, distributed work environments to help them see risk differently, build capacity to improve how work gets done, and operate safely with less effort. For more information, visit www.factorlab.com.

About Falfurrias Growth Partners
Falfurrias Growth Partners is an operationally focused middle-market investment fund focused on investing in high-growth companies in the software and business services sectors. The team is comprised of investors and proven operators, as well as in-house resources across strategy & market insights, finance / integration, human capital, and technology. The new fund strategy was launched in 2023 and is led by Cam Dyer, Partner and Chairman of Falfurrias Growth Partners I’s investment committee. The fund is managed by Falfurrias Management Partners, a Charlotte-based investment firm founded in 2006 by Hugh McColl Jr., former chairman and CEO of Bank of America; Marc Oken, former CFO of Bank of America; and Managing Partner Ed McMahan. The firm has raised approximately $4.0 billion across eight funds and invests in growing, middle-market businesses in sectors where the firm’s operational resources, relationships, and sector expertise can be employed to complement portfolio company executive teams in support of growth objectives. For more information, visit www.falfurrias.com.

SOURCE FactorLab

Hundreds of organizations including Nubank, Abridge, Applied Compute, and H Company use SkyPilot to turn fragmented clouds, clusters, and accelerators into one unified AI supercomputer

SAN FRANCISCO, July 21, 2026 — SkyPilot today announced it has launched from stealth with $20 million in seed funding. The company introduces SkyPilot Platform, a unified AI compute platform that helps frontier AI teams manage their AI compute across hyperscalers, neoclouds, Kubernetes clusters, and accelerator types.

The funding round was led by Lux Capital, with participation from Amplify Partners, Coatue Management, Foundation Capital, Race Capital, The House Fund, and leading technology operators including Ali Ghodsi, CEO of Databricks; Jeff Dean, Chief Scientist at Google; Guillermo Rauch, CEO of Vercel; Amjad Masad, CEO of Replit; Clem Delangue, CEO of Hugging Face; and Tristan Handy, CEO of dbt Labs.

SkyPilot was founded by Berkeley researchers Zongheng Yang, Zhanghao Wu, and Romil Bhardwaj alongside Databricks co-founder Ion Stoica and networking and cloud computing pioneer Scott Shenker, both Berkeley professors. The technology behind SkyPilot emerged from years of AI systems research at UC Berkeley.

Custom Intelligence Is Existential but Stalled by Fragmented AI Compute

From frontier AI labs to Fortune 500 enterprises, organizations are increasingly building custom intelligence: agents, applications, and post-trained models built on their own data and running on infrastructure they control.

Building custom intelligence at scale requires more compute than any single provider can offer. AI teams are assembling infrastructure across hyperscalers, neoclouds, Kubernetes clusters, and multiple generations of accelerators. As those environments become more distributed, managing AI compute has become a complex operational challenge that slows the development of custom intelligence.

SkyPilot turns fragmented clouds, clusters, and accelerators into one unified AI supercomputer. Through a unified control plane, organizations can develop, manage, monitor, and scale AI workloads across providers without changing how those workloads are built or operated. Today, SkyPilot powers AI compute across hundreds of organizations. Its open source project has surpassed 14 million downloads and attracted more than 280 contributors.

“Every organization is building custom intelligence around its own data and domains,” said Zongheng Yang, CEO and co-founder of SkyPilot. “The challenge is that the AI compute needed to build it is fragmented across clouds. SkyPilot gives frontier AI teams a single platform to manage that infrastructure so they can build custom intelligence faster.”

Introducing SkyPilot Platform

SkyPilot Platform is a managed AI compute platform for organizations operating large-scale AI infrastructure. Built on top of the SkyPilot open source project, it provides large GPU fleet operations, frontier workload support, standardized cluster management, workload orchestration, governance, and enterprise controls through a single platform.

Once customers bring their AI compute, the platform supports development, agentic workloads, training, reinforcement learning, inference, evaluations, and multi-cluster production serving. Customers also gain access to fleet-wide GPU health monitoring, automated remediation, high availability, team and quota management, single sign-on, and SOC 2 compliance.

Private preview customers have successfully used the platform to manage over 10,000 GPUs and support over 200 researchers per organization. Some saw performance improvements of up to 20x compared to SkyPilot open source thanks to the platform’s optimizations.

Product access is now open for select new customers. Prospective customers can visit skypilot.ai to learn more and request access at skypilot.ai/demo.

Leading AI Teams Use SkyPilot to Build Custom Intelligence Faster

Organizations across AI research, foundation model development, healthcare, financial services, and infrastructure use SkyPilot to operate large-scale AI workloads across fragmented compute environments. Major adopters include Nubank, Abridge, Applied Compute, H Company, Archer, and Hippocratic AI. The platform helps teams centralize infrastructure management, improve GPU utilization, accelerate time-to-production, and scale AI development without being tied to a single cloud or hardware provider.

Across those deployments, SkyPilot helps organizations centralize compute management, improve utilization across distributed GPU fleets, accelerate time-to-production, and reduce the operational burden of managing infrastructure across multiple providers.

Funding Supports Continued Growth

The seed funding will support product development, engineering expansion, go-to-market growth, and continued investment in the SkyPilot open source ecosystem.

“Every organization building custom intelligence is running into the same constraint. The compute they need exists, but it’s fragmented across clouds, clusters, and hardware generations,” said Brandon Reeves, Partner at Lux Capital. “SkyPilot brings that infrastructure together into a single operating environment, helping customers achieve double-digit improvements in GPU utilization while giving frontier AI teams the foundation to build and scale custom intelligence.

About SkyPilot

SkyPilot is the AI Compute Platform for frontier AI teams. The company offers products that manage AI infrastructure across hyperscalers and neoclouds through a unified control plane for training, reinforcement learning, inference, and production workloads.

The SkyPilot open source project has been downloaded more than 14 million times and is used by hundreds of organizations worldwide.

For more information about SkyPilot, visit: https://skypilot.ai

SOURCE SkyPilot

The Canadian-Based Superfood Brand Will Utilize The Funding to Scale U.S. Growth and Functional Wellness Innovation

TORONTO, July 21, 2026 — Organic Traditions, the family-founded Canadian superfood brand making functional wellness simple, announced today the close of a $10.5M Series A funding round ($15M CAD). The round was backed by a group of strategic angel investors with deep experience in consumer packaged goods, retail, technology, and operations, including executives and operators from FreshPet, Shopify, City National Bank, Frito-Lay, and Colgate-Palmolive.

The funding marks a major milestone for Organic Traditions as the brand enters its next stage of growth under second-generation leadership. With strong momentum in Canada and growing demand for simple, convenient functional products, the company will use the capital to accelerate U.S. retail expansion, grow its eCommerce business, advance innovation behind its Fiber Flow line, and invest in the team and infrastructure needed to support continued North American growth.

Founded more than 25 years ago by Jerry Zeifman and now led by his daughter, Ally Mamalider, Organic Traditions has grown from a Canadian superfood pioneer into one of the country’s leading wellness brands, with a portfolio spanning functional lattes, mushroom coffees, daily greens, fiber smoothies, and other superfood staples. Inspired by ancient wellness practices such as Ayurvedic medicine and cacao rituals, the brand modernizes time-tested ingredients into convenient formats that support energy, immunity, gut health, sleep, and overall wellness.

“This funding represents an exciting new chapter for Organic Traditions, but it does not change who we are,” said Ally Mamalider, second-generation founder and CEO of Organic Traditions. “For more than two decades, the brand has been rooted in the belief that real food can be transformative. This investment allows us to reach more consumers, scale the areas where we see the greatest opportunity, and continue making superfoods simple and accessible.”

Under the leadership of Mamalider, Organic Traditions has experienced 70% revenue growth over the past three years, driven by product innovation, digital expansion, and brand evolution. The brand is now projecting 36% revenue growth across Canada and the U.S. over the next 12 months, including 82% growth across U.S. retail and 64% growth across eCommerce. The brand is also planning to roll out in more than 1,500 U.S. retail doors this year.

Organic Traditions‘ innovation pipeline is being led by Fiber Flow, the brand’s newest product line designed to help consumers address one of the most significant nutritional deficiencies in North America: insufficient daily fiber intake. Each daily stick delivers 8g of fiber plus prebiotics and probiotics with zero sugar, in a clean, delicious, and easy-to-use format. Fiber Flow launched in Costco Canada earlier this year and sold out three times within its first two weeks of launching online. The platform is expected to grow by more than 200% over the next 12 months as Organic Traditions invests in additional line extensions and clinical trials.

“Organic Traditions is meeting a clear consumer need at the intersection of functional nutrition and convenience,” said Walter N. George, President of OT Investors LLC. “The brand has built meaningful trust with consumers over decades while also proving it can innovate quickly and scale across modern retail and digital channels. Ally and the team have a compelling vision for where functional wellness is going next, and we are excited to support that growth.”

The brand’s growth is also supported by strong consumer demand across its core product portfolio, including its best-selling Probiotic Matcha Latte, which has more than 2,000 five-star reviews, and Focus Fuel Mushroom Coffee, one of Canada’s leading mushroom coffees at major retailers.

Organic Traditions‘ products are available at leading natural and specialty retailers across North America, including Erewhon, Fresh Thyme, Earth Fare, MOM’s Organic Market, and regional leaders such as Jewel-Osco and Better Health, as well as more than 6,000 retail stores across Canada. The brand is also available online via Amazon and OrganicTraditions.com. For more information about Organic Traditions, please visit OrganicTraditions.com, or follow on Instagram @OrganicTraditions and on TikTok @OrganicTraditions.

About Organic Traditions
Organic Traditions is a family-owned superfood brand that creates thoughtfully crafted, nutrient-rich blends designed to make superfoods simple and accessible. Founded more than 25 years ago, the brand offers a portfolio of functional lattes, mushroom coffees, daily greens, fiber smoothies and superfood staples designed to fit seamlessly into everyday routines. Rooted in ancient wellness practices from Ayurveda to tea and cacao rituals, Organic Traditions brings time-tested ingredients into modern formats to help consumers support healthier daily habits. Learn more at organictraditions.com or follow along on Instagram and TikTok @OrganicTraditions.

MEDIA CONTACT
Amanda de la Cruz
650-224-5628
[email protected]

SOURCE Organic Traditions

Proceeds will be used to advance the company’s AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide

ALBUQUERQUE, N.M., July 21, 2026 — Karoo Health, a cardiovascular technology company building an operating system supporting cardiac care, today announced the closing of a $16.2 million Series A financing round co-led by 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, LLC, SpringRock Ventures, Hyde Park Angels (HPA), and other marquee investors.

As part of the financing, Lee Shapiro, Managing Partner at 7wire Ventures, and Jeff Stolte, Managing Partner at Allumia Ventures, will join Karoo’s Board of Directors.

Karoo is building an operating system for cardiovascular care, a technology platform designed to connect payers, providers, and patients through a unified data and workflow layer that supports earlier risk detection, care coordination, and overall improved cardiovascular disease outcomes.

The company’s mission is to free people from the pain of cardiovascular disease at scale through earlier detection, improved coordination, and data-driven care delivery.

“We’re at a seminal moment in our country’s fight against cardiovascular disease,” said Karoo Health CEO and Cofounder Ian Koons. “We intend to use this capital to take another major step toward becoming the solution that enables every American to access earlier, more coordinated, and more effective cardiovascular care.”

Cardiovascular disease remains the leading driver of healthcare costs in the United States, and care delivery remains fractured across clinical systems, claims data, pharmacy records, and care teams. This fragmentation contributes to delayed intervention, inconsistent chronic disease management, and avoidable hospital utilization, procedures, and testing.

“The challenge in cardiovascular care today isn’t a shortage of innovation but a system too fragmented to deliver it consistently,” said Lee Shapiro, Managing Partner of 7wire Ventures. “That fragmentation is precisely the kind of problem the right technology can solve. Karoo is creating the connective layer that lets care teams act on a complete picture of each patient, and its deployments are already producing meaningful reductions in avoidable utilization and cost. We are proud to co-lead this round.”

Today, Karoo supports a network of more than 600 cardiology providers across 11 states, operates programs with leading national and regional health plans and is launching with others later this year.

In deployed programs, independent analyses reported reductions of more than 40% in emergency department visits and inpatient admissions, and early results show a greater than 10% reduction in total cost of care throughout attributed populations.

“We’ve been waiting for a company with the technology, clinical vision, and leadership team capable of fundamentally changing how cardiac care is delivered. We believe Karoo Health is that company, and we’re proud to support their mission to improve outcomes for patients at scale while helping build a more proactive, connected, and effective model for cardiovascular care,” said Jeff Stolte, Managing Partner at Allumia Ventures.

Karoo will use proceeds from the financing to further develop its AI-native cardiovascular platform, including continued development of predictive models, clinical signal detection capabilities, and care coordination infrastructure. The company also plans to expand its engineering and clinical teams and continue scaling deployments with payer and provider partners.

About Karoo Health

Karoo Health is a cardiovascular technology company building the operating system for cardiovascular care. The company connects clinical, claims, pharmacy, and patient data to enable earlier risk detection, coordinated care, improved outcomes, and lower costs. Connect with the company on LinkedIn.

About 7wire Ventures

7wire Ventures is a venture capital firm investing in early-stage digital health companies that empower consumers to take greater control of their health and well-being. The firm focuses on technologies that advance a more connected, consumer-centric healthcare ecosystem. Founded by experienced operators and investors, 7wire partners closely with entrepreneurs to build category-defining companies, including Livongo, which merged with Teladoc Health in an $18.5 billion transaction. Through its operator-led approach and network of Strategic Limited Partners, including health plans, health systems, life sciences organizations, and self-insured employers, 7wire helps portfolio companies accelerate growth, expand market access, and drive meaningful innovation across healthcare. For more information, visit www.7wireventures.com.

About Allumia Ventures

Allumia Ventures is a leading healthcare venture capital firm focused on identifying and investing in best-in-class commercial-stage healthcare companies transforming healthcare through innovative technologies and care models. More than a source of capital, Allumia partners closely with entrepreneurs to accelerate adoption by leveraging deep relationships across the healthcare ecosystem and an extensive network of health systems and industry leaders. With roots in Providence, one of the nation’s largest integrated delivery networks, Allumia combines strategic expertise with a disciplined investment approach to help build companies that improve healthcare and deliver lasting impact. Connect with Allumia Ventures at www.allumiaventures.com.

SOURCE Karoo Health Inc

MONS, Belgium, July 21, 2026 — I-care Group, a global leader in Predictive Maintenance (PdM) and reliability solutions, today announced it has invested $25 million in its American subsidiary, reinforcing its long-term commitment to the United States and accelerating the expansion of its commercial and operational presence in one of the world’s largest industrial markets.

“With our established industrial customer base and increasing demand for our predictive maintenance and reliability solutions, the United States plays a central role in I-care’s long-term international development strategy and one of the Group’s strongest growth opportunities,” said Fabrice Brion, CEO of I-care Group. “This investment signals a commitment to I-care’s established presence in the United States, reinforcing its ability to serve industrial customers locally and supporting the company’s next phase of growth nationwide.”

The $25 million investment supports the expansion of I-care Reliability Inc.’s engineering, reliability, sales and marketing teams, reinforcing the company’s ability to serve customers through stronger local teams and a closer presence in the field.

“The United States is one of the world’s most dynamic markets for industrial innovation,” said Fabrice Brion, CEO of I-care Group. “More and more organizations are looking beyond individual technologies and want partners that combine advanced solutions with engineering expertise, reliability services, and long-term support. Strengthening I-care Reliability Inc. allows us to be even closer to our customers, helping them improve the reliability, productivity, and sustainability of their operations while accelerating the adoption of predictive maintenance across American industry.”

The investments in I-care Reliability Inc. are the latest milestone in I-care’s long-term growth strategy. Over the past few years, the Group has invested more than $50 million in developing its Wi-care™ technology, the I-see™ analytics platform, and its new IoT manufacturing facility in Belgium. These investments have expanded I-care’s innovation capabilities, strengthened its manufacturing footprint, and supported its continued international growth.

This long-term investment strategy has reinforced I-care’s position as a global leader in predictive maintenance and helped the company achieve unicorn status in 2025, with a valuation exceeding $1 billion.

About I-care

I-care is a global leader in predictive maintenance, helping industries optimize reliability and performance. With advanced technologies, including Wi-care™ vibration sensors and I-see™, an AI-driven platform, I-care monitors hundreds of thousands of machines worldwide and delivers actionable insights to external systems. Founded in 2004 in Belgium, I-care employs over 1,000 professionals across +35 offices in +15 countries, serving clients in more than 55 nations. Recognized for innovation, I-care has earned awards such as ADM’s Supplier Award, the Factory Innovation Award at Hannover Messe, and the Solutions Award at The Reliability Conference.

Learn more at www.icareweb.com.

SOURCE I-care

Led by Silicon Valley veteran Ari Zilka, the company unveils open-source SmartHub and commercial suite that is slashing production costs nearly 90% for a growing roster of Fortune 500 enterprises

SAN FRANCISCO, July 21, 2026 — MyDecisive today announced its emergence from stealth mode alongside a $12 million funding round. Founded in 2023 by Silicon Valley veteran and serial entrepreneur Ari Zilka, MyDecisive is launching a proven open-source foundation, SmartHub, and a suite of commercial products already driving value for some of the world’s largest enterprises.

As organizations move from AI experimentation to full-scale deployment, they face a growing challenge: human and AI developers are changing systems continuously, but most companies lack the visibility and capabilities to govern those changes safely at scale. MyDecisive closes that gap — giving enterprises an AI DevOps solution that keeps pace with every change, and with the resulting performance, security, and cost data production systems emit so enterprises can act instantly even under pressure before change becomes crisis.

“I know the cost of failed incident response from my days leading e-commerce operations, and as an investor, I’ve been looking for a true architectural shift to solve it. MyDecisive is that shift,” said Jason Pressman, MD of Copper Sky Capital. “They deliver exactly what the enterprise needs today: an autonomous system that resolves errors and prevents outages before human intervention is even required. Moving to AI DevOps is how companies will survive the next decade of compute. Ari and the MyDecisive team are executing on a vision that no one else has been able to figure out.”

Open-Source Foundation and Commercial Suite

MyDecisive’s architecture operates precisely where modern enterprises need it most as they adopt AI: at the edge, inside their own cloud and on-premise.

• SmartHub (The Open-Source Foundation): Built as a Kubernetes and OpenTelemetry-native, self-managing cluster, SmartHub gives engineering teams ultimate control over their telemetry data. It bypasses the traditional model of shipping massive, unoptimized data streams to expensive third-party dashboards.
• Octant (The Enterprise Commercial Suite): Building on top of the SmartHub foundation, MyDecisive today announced the general availability of Octant. This suite of enterprise-ready products seamlessly integrates with SmartHub to provide advanced governance, robust security protocols, and out-of-the-box automation.

Octant cuts enterprise time-to-value down to a single day. Capabilities like enhanced error management, self-trained anomaly detection with automated runbook execution, cloud auto-scaling, and security log optimization can be added by any engineer in hours, reducing the total operating cost of production systems by nearly 90%.

“For the past three years, we have been quietly building the infrastructure that enterprises actually need, rather than the hype they’ve been sold,” said Ari Zilka, Founder and CEO of MyDecisive. “By rooting our commercial offerings in the open-source SmartHub platform, we are giving organizations the flexibility of open standards combined with the power and security of enterprise-grade tooling. Our customers aren’t just testing our AI; they are operating it in production at scale, with immediate same-day value.”

Enterprise Market Momentum

MyDecisive exits stealth with significant market traction. The company is already powering production workloads for major enterprise customers and boasts an accelerating pipeline of successful deployments across the financial services, retail, telecommunications, and healthcare sectors.

“When IT leaders are ready to fully optimize their production observability posture, they turn to Intelli Platforms. Powered by MyDecisive, we look beyond basic cost control to holistically optimize production operations,” said Ross Mistretta, Chief Technology & Delivery Officer at Intelli Platforms. “This delivers bulletproof stability and precise control over all production costs, not just the observability tax. We are actively working with a premier roster of enterprise operations teams who have hit a wall with standard dashboards and endless MTTx cycles, and are demanding a smarter, autonomous path forward.”

To learn more about MyDecisive, the SmartHub platform, and its suite of enterprise products, visit mydecisive.ai.

About MyDecisive

MyDecisive is the AI DevOps platform that unifies engineering, operations, and FinOps to secure and scale mission-critical applications. Built on the open-source SmartHub foundation, MyDecisive intercepts telemetry at the edge, enabling enterprises to autonomously resolve incidents, govern AI workloads, and drastically reduce production observability costs. Founded in 2023 and headquartered in Silicon Valley, MyDecisive powers the infrastructure of the world’s most demanding organizations, ensuring legacy and AI systems run flawlessly side by side. For more information, visit www.mydecisive.ai.

SOURCE MyDecisive

Chief Revenue Officer, Vice President of Customer Success, and Senior Vice President of People join Assort Health following its $120 million Series C and accelerating customer demand to scale the most widely-used AI agents platform for the patient journey

SAN FRANCISCO, July 21, 2026 — Assort Health, the most widely-used AI agents platform for the patient journey, today announced three senior executive hires, including Jon Corn as Chief Revenue Officer, Kristina Kemp as Vice President of Customer Success, and Emil Yeargin as Senior Vice President of People.

These appointments come as health systems and provider groups move beyond AI pilots and point solutions toward enterprise-scale platforms that automate patient access across scheduling, intake, referrals, medication refills, lab requests, and payments. As more organizations standardize on a single AI platform, Assort is expanding its commercial, customer, and organizational leadership to meet accelerating demand.

The leadership expansion follows Assort’s $120 million Series C financing, led by Menlo Ventures, bringing total funding to $222 million, and comes just weeks after more than 200 healthcare leaders gathered at the company’s annual Ascend customer summit.

Over the last 15 months, Assort has grown revenue 20x while expanding its platform across the healthcare front office. Today, Assort’s platform is powered by more than 200 million patient interactions, 62,000 care protocols, and 1.6 million decision pathways, creating the largest proprietary specialty dataset in healthcare.

“Building great AI is only part of the challenge,” said Jon Wang, founder and co-CEO of Assort Health. “Turning it into the AI agents platform for the country’s largest provider groups and health systems requires a different kind of company. Jon, Kristina, and Emil have each helped organizations navigate moments like this before. They’ll help us grow without losing the speed, customer focus, and product discipline that got us here.”

Jon Corn joins as Chief Revenue Officer

Jon Corn joins Assort as Chief Revenue Officer following a tenure at Samsara, where he helped build a GTM engine that wins large, complex customers. He grew the company’s enterprise annual recurring revenue by 1,220% and built an organization of more than 100 team members, leading the company’s first Fortune 10 customer relationship. In his new role, he will lead Assort’s go-to-market team with a focus on large-scale health systems and provider groups.

“Healthcare leaders aren’t looking for another AI vendor. They’re looking for a platform they can trust to become part of how they operate,” said Corn. “What convinced me to join Assort wasn’t just the technology. It was the combination of deep healthcare expertise, extraordinary customer trust, and a product that’s already delivering meaningful results at scale. That’s incredibly rare.”

Kristina Kemp joins as Vice President of Customer Success

After advising Assort for the past 15 months, Kristina Kemp joins the company now full-time as Vice President of Customer Success. She previously spent nearly seven years leading customer success at Luma Health, where she helped make expansion revenue the company’s largest driver of growth. At Assort, she will help healthcare organizations maximize the value of the platform while building long-term strategic partnerships.

Emil Yeargin joins as Senior Vice President of People

Emil Yeargin joins Assort as Senior Vice President of People to build the organization required for the company’s next stage of growth. Most recently at Squint, he doubled headcount while building the systems and leadership practices needed to scale rapidly. Earlier leadership roles at Gusto, Lyft, and Okta gave him experience helping high-growth companies navigate periods of rapid expansion. At Assort, he will lead the company’s people strategy, real estate portfolio, organizational development, and talent programs.

“Building an enduring company means raising the bar with every hire,” said Jeffery Liu, Founder and Co-CEO of Assort Health. “Jon, Kristina, and Emil bring experience we’ve never had before, and they’ll make everyone around them better. That’s how great organizations compound: not just through technology, but through the people who build it together.”

Assort plans to continue expanding across engineering, operations, customer success, and go-to-market throughout 2026.

For more information, visit assorthealth.com.

About Assort Health

Assort Health is the most-widely used AI agents platform for the patient journey, from scheduling and intake to referrals, forms, document processing, medication refills, and payments. It is built on 200 million specialty patient interactions and a model that updates in real time to handle the complexity of healthcare that general-purpose AI can’t. That foundation now powers patient access across multi-site practices, multi-specialty groups, and health systems. Customers see a 5% lift in appointment volume, a 115% increase in labor capacity, and a 4.3 out of 5 patient satisfaction score. The platform integrates natively with leading EHR and practice management systems, including Epic and Athena, enabling deployment without disrupting existing clinical workflows. Provider groups and health systems turn to Assort when the complexity outgrows their existing tools. To learn more, visit assorthealth.com.

Media Contact: Kara Spak, 120/80 MKTG, [email protected]

SOURCE Assort Health

Dr. Haumann brings decades of respiratory drug expertise to support next phase of company growth

CEO appointment follows recent clinical and corporate milestones including Phase 2b CARDINAL trial initiation and Series B financing

ATLANTA, July 21, 2026 — Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced the appointment of Brett Haumann, MBBCh, MBA as Chief Executive Officer.

Dr. Haumann has been serving as a non-executive member of the Altesa Board and joins the executive team at a time of accelerating momentum, following the company’s oversubscribed $75 million Series B round and launch of the Phase 2b CARDINAL study evaluating vapendavir for its potential as a transformational treatment for rhinovirus in patients with COPD — the leading cause of acute exacerbations.

“Dr. Haumann’s deep experience building and leading global respiratory and anti-infective programs makes him the ideal leader for Altesa at this pivotal juncture,” said Moncef Slaoui, Board Chair of Altesa BioSciences, and former Chairman of both Global Research and Development and the Vaccine Division at GSK, and former Chief Scientific Advisor to the U.S. government’s Operation Warp Speed. “His track record, vision, and operational excellence align perfectly with Altesa’s next phase — advancing our late-stage asset and broadening our impact on chronic lung disease. With Brett at the helm, I am confident we will deliver on the promise of vapendavir for patients and caregivers whose needs have gone unmet for too long.”

A 30-year industry veteran recognized for his leadership in respiratory medicine, Dr. Haumann most recently served as CEO of RIGImmune and previously held Chief Medical Officer roles at Circassia, Theravance Biopharma, and ReViral, spanning both public and private biotechs in the U.S. and U.K. Earlier at GSK — alongside Dr. Katharine Knobil, M.D., Chief Medical Officer of Altesa BioSciences, and Dr. Slaoui — Dr. Haumann led programs from early drug discovery through commercialization across anti-infectives, immunology and respiratory portfolios. Dr. Haumann has also served as a non-executive director on a number of private and public biotech boards, and as a venture partner with SV Health Investors.

“Altesa is an incredibly exciting company with a remarkable focus on patients,” said Dr. Haumann. “The innovative new science underpinning vapendavir — and the rapid progress achieved by this extraordinary team this year, including the initiation of the Phase 2b CARDINAL study in COPD — are testimony to the company’s laser focus and firm commitment to advancing vapendavir. I am honored to lead Altesa at this key moment in time and look forward to delivering on the company’s mission to meaningfully improve the lives of patients with chronic respiratory disease.”

About Vapendavir
Vapendavir is an investigational oral medicine in development by Altesa BioSciences. Recently, Altesa announced that vapendavir improved symptoms, reduced duration of illness and viral load, and maintained small airway function in COPD patients experimentally challenged with rhinovirus in a Phase 2a trial. Vapendavir is now in late-stage clinical development and, if approved, has the potential to prevent the most common cause of COPD exacerbations, improve quality of life, and generate significant reductions in healthcare costs.

About the CARDINAL Study
The CARDINAL clinical trial is a Phase 2b multinational, randomized, placebo-controlled study in COPD patients experiencing rhinovirus infections that will enroll 900 people with COPD across the U.S. and U.K. The trial was designed to reflect real-world care models, proactively identifying and supporting those at greatest risk. Participants will be closely monitored over time and, upon confirmed rhinovirus infection, will be randomized to receive one of two doses of vapendavir or placebo. The trial’s primary objective is to assess improvement in respiratory symptoms using established patient-reported outcomes, with additional endpoints evaluating time to symptom resolution, quality of life, healthcare resource utilization, and lung function.

About Altesa BioSciences, Inc.
Altesa BioSciences is a clinical-stage pharmaceutical company led by global experts in respiratory medicine and infectious diseases. Altesa is dedicated to improving the lives of people with chronic lung diseases, including COPD and asthma, by treating the principal cause of exacerbations and pathological inflammation — viral respiratory infections. www.altesa.com

Media Contact: Peg Rusconi
Email: [email protected]

SOURCE Altesa Biosciences Inc.